Indian Firm’s Novel Antibiotic ‘Zaynich’ Gets FDA Nod for Review — A Big Step Against Drug-Resistant Infections

The United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Zaynich, a first-in-class antibiotic developed by Wockhardt Ltd., marking a historic milestone — it’s the first time an Indian company’s new chemical antibiotic has reached this stage.

As a doctor, I view this as a potentially game-changing moment in our fight against antimicrobial resistance (AMR). If Zaynich clears full approval, it could become a powerful option for treating infections caused by resistant bacteria — a growing challenge in routine and hospital settings. This makes me hopeful for better clinical tools ahead. However, until full data and indication details are available, prudent use and continued vigilance remain essential.